PC14586

DRUG4 trials

Sponsors

Pmv Pharmaceuticals Inc., PMV Pharmaceuticals, Inc

Conditions

Healthy VolunteersLocally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation

Phase 1

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

CompletedNCT05249348

PMV Pharmaceuticals, IncHealthy Volunteers

Start: 2021-12-20End: 2022-06-09Updated: 2024-11-13

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

CompletedNCT06054464

PMV Pharmaceuticals, IncHealthy Volunteers

Start: 2023-09-19End: 2024-02-06Updated: 2024-11-13

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

CompletedNCT06362642

PMV Pharmaceuticals, IncHealthy Volunteers

Start: 2024-03-28End: 2024-10-22Updated: 2024-11-13

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE).

RecruitingCTIS2023-504251-27-00

Pmv Pharmaceuticals Inc.Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation

Start: 2024-05-27Target: 105Updated: 2026-01-14